Advanced MRI Techniques: Diagnosis and Follow-Up of Multiple Sclerosis

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Jun 19

PMID 38893646

Authors

Riccardo Nistri

Antonio Ianniello

Valeria Pozzilli

Costanza Gianni

Carlo Pozzilli

Affiliations

Soon will be listed here.

Abstract

Brain and spinal cord imaging plays a pivotal role in aiding clinicians with the diagnosis and monitoring of multiple sclerosis. Nevertheless, the significance of magnetic resonance imaging in MS extends beyond its clinical utility. Advanced imaging modalities have facilitated the in vivo detection of various components of MS pathogenesis, and, in recent years, MRI biomarkers have been utilized to assess the response of patients with relapsing-remitting MS to the available treatments. Similarly, MRI indicators of neurodegeneration demonstrate potential as primary and secondary endpoints in clinical trials targeting progressive phenotypes. This review aims to provide an overview of the latest advancements in brain and spinal cord neuroimaging in MS.

Citing Articles

Ultra-High Contrast (UHC) MRI of the Brain, Spinal Cord and Optic Nerves in Multiple Sclerosis Using Directly Acquired and Synthetic Bipolar Filter (BLAIR) Images.

Condron P, Cornfeld D, Bydder M, Kwon E, Whitehead K, Pravata E Diagnostics (Basel). 2025; 15(3).

PMID: 39941259 PMC: 11816702. DOI: 10.3390/diagnostics15030329.

Differential Analysis of Venous Sinus Diameters: Unveiling Vascular Alterations in Patients with Multiple Sclerosis.

Tunc A, Danisan G, Taydas O, Kara A, Oncel S, Ozdemir M Diagnostics (Basel). 2024; 14(16).

PMID: 39202247 PMC: 11353770. DOI: 10.3390/diagnostics14161760.

References

Filippi M, Rocca M, Sormani M, Pereira C, Comi G . Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. Magn Reson Imaging. 1999; 17(7):979-84. DOI: 10.1016/s0730-725x(99)00049-1. View

Ghasemi N, Razavi S, Nikzad E . Multiple Sclerosis: Pathogenesis, Symptoms, Diagnoses and Cell-Based Therapy. Cell J. 2017; 19(1):1-10. PMC: 5241505. DOI: 10.22074/cellj.2016.4867. View

Chawla S, Kister I, Sinnecker T, Wuerfel J, Brisset J, Paul F . Longitudinal study of multiple sclerosis lesions using ultra-high field (7T) multiparametric MR imaging. PLoS One. 2018; 13(9):e0202918. PMC: 6136714. DOI: 10.1371/journal.pone.0202918. View

Liu C, Li W, Tong K, Yeom K, Kuzminski S . Susceptibility-weighted imaging and quantitative susceptibility mapping in the brain. J Magn Reson Imaging. 2014; 42(1):23-41. PMC: 4406874. DOI: 10.1002/jmri.24768. View

Castellaro M, Tamanti A, Pisani A, Pizzini F, Crescenzo F, Calabrese M . The Use of the Central Vein Sign in the Diagnosis of Multiple Sclerosis: A Systematic Review and Meta-analysis. Diagnostics (Basel). 2020; 10(12). PMC: 7760678. DOI: 10.3390/diagnostics10121025. View

Panda A, Mehta B, Coppo S, Jiang Y, Ma D, Seiberlich N . Magnetic Resonance Fingerprinting-An Overview. Curr Opin Biomed Eng. 2018; 3:56-66. PMC: 5984038. DOI: 10.1016/j.cobme.2017.11.001. View

Arnold D, Gold R, Kappos L, Bar-Or A, Giovannoni G, Selmaj K . Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study. J Neurol. 2014; 261(12):2429-37. PMC: 4242981. DOI: 10.1007/s00415-014-7504-7. View

Buxton R . The physics of functional magnetic resonance imaging (fMRI). Rep Prog Phys. 2013; 76(9):096601. PMC: 4376284. DOI: 10.1088/0034-4885/76/9/096601. View

Absinta M, Sati P, Schindler M, Leibovitch E, Ohayon J, Wu T . Persistent 7-tesla phase rim predicts poor outcome in new multiple sclerosis patient lesions. J Clin Invest. 2016; 126(7):2597-609. PMC: 4922708. DOI: 10.1172/JCI86198. View

10.

Moccia M, Ruggieri S, Ianniello A, Toosy A, Pozzilli C, Ciccarelli O . Advances in spinal cord imaging in multiple sclerosis. Ther Adv Neurol Disord. 2019; 12:1756286419840593. PMC: 6477770. DOI: 10.1177/1756286419840593. View

11.

Pardo G, Jones D . The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations. J Neurol. 2017; 264(12):2351-2374. PMC: 5688209. DOI: 10.1007/s00415-017-8594-9. View

12.

Hori M, Maekawa T, Kamiya K, Hagiwara A, Goto M, Takemura M . Advanced Diffusion MR Imaging for Multiple Sclerosis in the Brain and Spinal Cord. Magn Reson Med Sci. 2022; 21(1):58-70. PMC: 9199983. DOI: 10.2463/mrms.rev.2021-0091. View

13.

Calabrese M, Filippi M, Gallo P . Cortical lesions in multiple sclerosis. Nat Rev Neurol. 2010; 6(8):438-44. DOI: 10.1038/nrneurol.2010.93. View

14.

Kuhlmann T, Ludwin S, Prat A, Antel J, Bruck W, Lassmann H . An updated histological classification system for multiple sclerosis lesions. Acta Neuropathol. 2016; 133(1):13-24. DOI: 10.1007/s00401-016-1653-y. View

15.

Calvi A, Haider L, Prados F, Tur C, Chard D, Barkhof F . In vivo imaging of chronic active lesions in multiple sclerosis. Mult Scler. 2020; 28(5):683-690. PMC: 8978472. DOI: 10.1177/1352458520958589. View

16.

Krajnc N, Schmidbauer V, Leinkauf J, Haider L, Bsteh G, Kasprian G . Paramagnetic rim lesions lead to pronounced diffuse periplaque white matter damage in multiple sclerosis. Mult Scler. 2023; 29(11-12):1406-1417. PMC: 10580674. DOI: 10.1177/13524585231197954. View

17.

Harrison D, Roy S, Oh J, Izbudak I, Pham D, Courtney S . Association of Cortical Lesion Burden on 7-T Magnetic Resonance Imaging With Cognition and Disability in Multiple Sclerosis. JAMA Neurol. 2015; 72(9):1004-12. PMC: 4620027. DOI: 10.1001/jamaneurol.2015.1241. View

18.

Stroman P, Wheeler-Kingshott C, Bacon M, Schwab J, Bosma R, Brooks J . The current state-of-the-art of spinal cord imaging: methods. Neuroimage. 2013; 84:1070-81. PMC: 4371133. DOI: 10.1016/j.neuroimage.2013.04.124. View

19.

Cagol A, Cortese R, Barakovic M, Schaedelin S, Ruberte E, Absinta M . Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis. JAMA Neurol. 2023; 81(2):143-153. PMC: 10714285. DOI: 10.1001/jamaneurol.2023.4737. View

20.

Arnold D, Piani-Meier D, Bar-Or A, Benedict R, Cree B, Giovannoni G . Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial. Mult Scler. 2022; 28(10):1526-1540. PMC: 9315182. DOI: 10.1177/13524585221076717. View